New paper calls upon states to cease experimenting with lethal injection drugs and comply with FDA regulations

May 15, 2014 by Susan Sperry

The Johns Hopkins Clinic for Public Health Law and Policy at the Bloomberg School of Public Health has crafted an evidence-based paper that presents a new perspective on the legality of the lethal injection process in the United States. The shortage of the combination of the three drugs previously used in States that use lethal injection to carry out capital punishment, in an attempt to comply with the Eighth Amendment prohibition on cruel and unusual punishment, has led to unregulated and experimental protocols in the lethal injection process that violate existing federal laws. The paper argues that state Departments of Corrections are violating U.S. Food and Drug Administration (FDA) investigational new drug regulations by experimenting with lethal injection drugs when carrying out executions. The paper's completion comes on the heels of the botched lethal injection execution that occurred recently in Oklahoma.

Under federal law, state Departments of Corrections are required to submit an Investigational New Drug (IND) application when any is administered, dispensed or used outside of a medical practice on one or more human subjects. The Federal Food, Drug and Cosmetic Act and the FDA's IND regulations cite specific requirements for clinical investigations, which would include a state's experimentation with new lethal drug combinations during executions.

"The IND process – fortified by the FDA's unmatched expertise with drug protocols would ensure that the Department's of Corrections protocols are effective in reducing the risk that will subject a condemned prisoner to pain that would violate the Eighth Amendment," said Stephen Teret, JD, MPH, founding director of the Clinic for Public Health Law & Policy. "FDA law states that an IND application must be submitted when any new drug protocol or experiment is undertaken on a human outside of a medical practice or a doctor's office. The laws are in place, the process just isn't being implemented."

The paper concludes that as states continue to grapple with drug shortages and to experiment with new combinations and dosages of drugs used to carry out executions, they should adhere to the guidelines put in place by Congress over fifty years ago to safeguard the human subjects of clinical investigations, including prisoners on death row. The paper recommends that executions should be halted by the courts until an FDA approved protocol for lethal injection can be established and approved.

Explore further: Could obstacles to lethal injection lead to an end to the death penalty?​​

Related Stories

Could obstacles to lethal injection lead to an end to the death penalty?​​

February 13, 2014
Access to required anesthetic agents for a lethal injection is quickly disappearing, leaving the future of the death penalty in the United States in question.

Execution drugs spark controversy as supplies dwindle

October 11, 2013
The United States is turning to new drugs for lethal injections as supplies of the current standard dwindle, sparking lawsuits from death row prisoners that the changes will cause undue suffering.

Pharmacists urged not to assist US executions (Update)

March 25, 2014
Several human rights and anti-death penalty groups have asked the American Pharmacists Association to prohibit members from participating in executions, a request that comes as states increasingly turn to pharmacists for ...

US state turns to different lethal injection drug

April 20, 2013
After surrendering its supply of a lethal injection drug to federal agents in 2011, Arkansas turned to a somewhat surprising place to look for another drug: a list from lawyers for several death row inmates.

Another manufacturer blocks drug for execution use (Update)

September 27, 2012
(AP)—A manufacturer of the anesthetic blamed for Michael Jackson's death said Thursday it won't sell propofol for use in U.S. executions, a setback for Missouri and other states looking for an alternative after other drug ...

Recommended for you

Cholesterol-lowering drugs may fight infectious disease

August 21, 2017
That statin you've been taking to lower your risk of heart attack or stroke may one day pull double duty, providing protection against a whole host of infectious diseases, including typhoid fever, chlamydia, and malaria.

Data revealed under FOI shows benefits of multiple sclerosis drug currently blocked by regulators

August 17, 2017
A drug that is blocked by the EU regulatory system has now been found to improve the quality of life of people with multiple sclerosis (MS), according to a study by Queen Mary University of London (QMUL).

Opioids overused in migraine treatment, regardless of race, study finds

August 17, 2017
African-Americans are more likely to experience debilitating migraine headaches than whites, but a new study probing the issue found no evidence of racial disparities in treatment practices.

Finding better ways to reduce serious drug side effects

August 14, 2017
Many of the medicines we depend on to treat disease—and even to save our lives—pose potentially serious risks along with their benefits. Data from the U.S. Centers for Disease Control and Prevention indicate that about ...

Ultrasound-triggered liposomes for on-demand, local anesthesia

August 10, 2017
Researchers at Boston Children's Hospital have found a new way to non-invasively relieve pain at local sites in the body; such systems could one day improve pain management by replacing addictive opioids and short-lasting ...

Independent pharmacies and online coupons help patients save money on drugs

August 8, 2017
Uninsured patients or those with limited prescription drug coverage can save significant money by buying their drugs at independent pharmacies instead of big box, grocery or chain drug stores and by using discount coupons, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.